Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | PHASE2 | RECRUITING | 70 | — | — | Jun 23, 2023 | Sep 1, 2026 | May 16, 2025 | 30 | United States, France +3 |
Number of patients with pathological Complete Response (pCR)
Number of patients with adverse events (AEs) and serious adverse events (SAEs).
| Arm | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | EXPERIMENTAL | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
| Name | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | DRUG | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
Inclusion Criteria: 1. Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC resectable (Stage IIA to Stage IIIA) disease (according to Version 8 of IASLC Staging Manual in Thoracic Oncology 2016. 2. WHO Performance Status or Eastern Cooperative Onc...